Effects of AFO use on walking in boys with duchenne muscular dystrophy: A pilot study

Pediatric Physical Therapy

Volumn 27, Issue 1, 2015, Pages 24-29

  Townsend, Elise L ^a,b   Tamhane, Himani ^d   Gross, K Douglas ^a,c  

^a MGH INSTITUTE OF HEALTH PROFESSIONS   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Health East Medical Center   (United States)

Author keywords

Child; Duchenne muscular dystrophy; Foot orthoses; Gait; Male; Physical endurance; Walking

Indexed keywords

ADOLESCENT; ANKLE; CHILD; CONTROLLED STUDY; CROSSOVER PROCEDURE; EXERCISE TEST; FALLING; FOOT; HUMAN; MALE; MUSCULAR DYSTROPHY, DUCHENNE; ORTHOSIS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; WALKING;

ACCIDENTAL FALLS; ADOLESCENT; ANKLE; CHILD; CROSS-OVER STUDIES; EXERCISE TEST; FOOT; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; ORTHOTIC DEVICES; PILOT PROJECTS; WALKING;

EID: 84912036155     PISSN: 08985669     EISSN: 1538005X     Source Type: Journal    
DOI: 10.1097/PEP.0000000000000099     Document Type: Article

References (32)

1. D'Angelo MG, Berti M, Piccinini L, et al. Gait pattern in Duchenne muscular dystrophy. Gait Posture. 2009;29(1):36-41.
2. Case L. Physical Therapy Management of Dystrophinopathies (Duchenne and Becker Muscular Dystrophy). Presentation at: Parent Project Muscular Dystrophy Annual Conference; 2006:1-45. www.parentprojectmd.org/site/DocServer/PT handout-parent project mtg-2006-L-Case.pdf?docID=4121.
3. Merlini L,Cicognani A,Malaspina E, et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve. 2003;27(2):222-227.
4. Balaban B, Matthew D, Clayton G, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: longterm effect. Am J Phys Med Rehabil. 2005;84(11):843-850.
5. Yilmaz O., Karaduman A, Topaloglu H. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur J Neurol. 2004;11(8):541-544.
6. Bushby K, Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from international working group meetings. Clin Invest (Lond). 2011;1(9):1217-1235.
7. Bakker JP, De Groot IJ, Beckerman H, de Jong BA, Lankhorst GJ. The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature. Clin Rehabil. 2000;14(4):343-359.
8. Stevens P. Lower limb orthotic management of Duchenne muscular dystrophy: a literature review. JPO. 2006;18(4):111.
9. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9(2):177-189.
10. Stuberg WA. Muscular dystrophy and spinal muscular atrophy. In: Campbell SK, Palisano RJ, Orlin MN, eds. Physical Therapy for Children. 4th ed. St Louis, MO: Elsevier Saunders; 2012:353-365.
11. Meier R. Using controlled motion to manage gait. Adv Phys Therap Rehab Med. 2008;19(20):42.
12. Danielsson A, Sunnerhagen KS. Energy expenditure in stroke subjects walking with a carbon composite ankle foot orthosis. J Rehabil Med. 2004;36(4):165-168.
13. Mayhew JE, Florence JM, Mayhew TP, et al. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve. 2007;35(1):36-42.
14. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve. 2010;42(6):966-974.
15. McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013;48(3):357-368.
16. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41(4):500-510.
17. Wondra V, Pitteti K, Beets M. Gait parameters in children with motor disabilities using an electronic walkway system: assessment of reliability. Pediatr Phys Ther. 2007;19:326-331.
18. Portney LG, Watkins MP. Descriptive statistics. In:Foundations of Clinical Research: Applications to Practice . 3rd ed. Upper Saddle River, NJ: Pearson; 2009:390-391.
19. Vignos PJ Jr, Spencer GE Jr, Archibald KC. Management of progressive muscular dystrophy of childhood. JAMA. 1963;184(2):89-96.
20. Mazzone EG, Vasco G, Somani MP, et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology. 2011;77:250-256.
21. McDonald C. CINRG Duchenne natural history study overview and future plans; ambulatory clinical endpoints in DMD. In: NIDRR State of the Science Meeting on Outcome Measures in Duchenne Muscular Dystrophy. Crystal City, VA; 2012.
22. McDonald CM, Abresch RT, Carter GT, et al. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1995;74(5):S93.
23. Bushby K, Bourke J, Bullock R, Eagle M, Gibson M, Quinby J. The multidisciplinary management of Duchenne muscular dystrophy. Current Paediatrics. 2005;15(4):292-300.
24. King W, Ruttencutter R, Nagaraja H, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68(19):1607-1613.
25. Beenakker EA, Fock JM, Van Tol MJ, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol. 2005;62(1):128-132.
26. Sharma KR, Mynhier MA, Miller RG. Muscular fatigue in Duchenne muscular dystrophy. Neurology. 1995;45(2):306-310.
27. McDonald CM. Physical activity, health impairments, and disability in neuromuscular disease. Am J PhysMed Rehabil. 2002;81(11):S108-S120.
28. Mendell J, Moxley R, Griggs R, et al. Randomized, double-blind sixmonth trial of prednisone in Duchenne's muscular dystrophy. NEngl J Med. 1989;320(24):1592-1597.
29. Griggs RC, Moxley RT III, Mendell JR, et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Arch Neurol. 1991;48(4):383-388.
30. Dubowitz V, Kinali M, Main M, Mercuri E, Muntoni F. Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol. 2002;6(3):153-159.
31. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the longterm treatment of early cases of Duchenne dystrophy. Neuromuscular Disord. 2002;12:S169-S174.
32. Straathof CS, Overweg-Plandsoen WC, van den Burg GJ, van der Kooi AJ, Verschuuren JJ, de Groot IJ. Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy. J Neurol. 2009;256(5):768-773.